Skip to content 
Stroke is commonly known as “stroke”
If it happens, you must seek medical attention immediately
Missing the “golden period” of treatment will endanger life
Can we stock up on stroke medicine in advance?
Give brain protection at the first opportunity?
A new drug solves this problem
Taken sublingually for rapid effectiveness
Effectively reduce brain cell death rate
Extending the “time window” for stroke treatment
Providing doctors with more treatment space
Recently, good news came from Nanjing Jiangbei New District company Xiansheng Pharmaceutical: its innovative drug Xinbixin® Sublingual Tablets (generic name: Idarubicin and Urocampal Sublingual Tablets), used to treat stroke, was approved for marketing by the National Medical Products Administration.
This drug can improve neurological symptoms, daily living activities and functional impairment caused by acute ischemic stroke. In the future, it will be available for purchase with prescription in hospitals and will also be available on Internet hospitals.
Cerebral stroke, commonly known as “stroke”, is the leading cause of death and disability among Chinese residents. Stroke is divided into ischemic stroke and hemorrhagic stroke. More than 60% of strokes in China are ischemic strokes, which are often called “cerebral infarctions”. Blood vessels are blocked and blood cannot flow into the brain. Hemorrhagic stroke refers to sudden rupture of blood vessels in the brain, causing bleeding. Both types of strokes will cause brain tissue damage, and will lead to disability or death after clinical symptoms appear.
In 2020, Simcere Pharmaceuticals was approved to market a drug for the treatment of cerebral stroke – Simcere® Injection. This drug is the only innovative drug approved in the field of stroke in the world since 2015, and has helped more than 3 million stroke patients.
However, the injection of Xinbixin® requires patients to receive intravenous infusion in the hospital, and stroke is sudden. How to make the product more convenient and timely to expand to the whole process of patients’ onset, hospitalization, home treatment and rehabilitation? In 2016, the R&D team of Simcere Pharmaceuticals began to explore the development of Xinbixin® sublingual tablets.
“This is a brand-new dosage form. Once the drug is placed under the tongue, it will quickly disintegrate when it comes into contact with saliva and be absorbed into the blood and brain through the sublingual venous plexus, thereby exerting its therapeutic effect.” A relevant staff member of Innovent said, “Compared with general oral dosage forms, sublingual tablets do not need to be metabolized and attenuated by the liver and can be more fully absorbed and utilized by the human body.”
The innovative drug delivery method allows patients to take medication as soon as a stroke occurs to protect brain cells in a timely manner. They can also take medication conveniently at home after discharge, which increases the flexibility of stroke treatment and enables earlier treatment and more adequate treatment courses.
In addition to being more convenient in terms of medication, the efficacy of the Cefixime® sublingual tablets is also guaranteed.
The drug was jointly developed by Innovent and Ningdan Pharmaceuticals. It is a dual-target brain cell protector containing two active ingredients, edaravone and dextroborneol, which synergizes the antioxidant and anti-inflammatory effects. As an important research result of the National Key Laboratory of Neuro-Oncology Drug Development, clinical studies of this drug have shown that the sublingual tablets of Xinbixin® can significantly reduce brain cell damage caused by acute ischemic stroke.
